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CCCTC-binding factor is essential to the maintenance
and quiescence of hematopoietic stem cells in mice
Tae-Gyun Kim1,2,3,4, Sueun Kim1,2,4, Soyeon Jung1, Mikyoung Kim1, Bobae Yang1,2, Min-Geol Lee2,3
and Hyoung-Pyo Kim1,2
Hematopoiesis involves a series of lineage differentiation programs initiated in hematopoietic stem cells (HSCs) found in
bone marrow (BM). To ensure lifelong hematopoiesis, various molecular mechanisms are needed to maintain the HSC pool.
CCCTC-binding factor (CTCF) is a DNA-binding, zinc-ﬁnger protein that regulates the expression of its target gene by organizing
higher order chromatin structures. Currently, the role of CTCF in controlling HSC homeostasis is unknown. Using a tamoxifen-
inducible CTCF conditional knockout mouse system, we aimed to determine whether CTCF regulates the homeostatic
maintenance of HSCs. In adult mice, acute systemic CTCF ablation led to severe BM failure and the rapid shrinkage of multiple
c-Kithi progenitor populations, including Sca-1+ HSCs. Similarly, hematopoietic system-conﬁned CTCF depletion caused an acute
loss of HSCs and highly increased mortality. Mixed BM chimeras reconstituted with supporting BM demonstrated that CTCF
deﬁciency-mediated HSC depletion has both cell-extrinsic and cell-intrinsic effects. Although c-Kithi myeloid progenitor cell
populations were severely reduced after ablating Ctcf, c-Kitint common lymphoid progenitors and their progenies were less
affected by the lack of CTCF. Whole-transcriptome microarray and cell cycle analyses indicated that CTCF deﬁciency results in
the enhanced expression of the cell cycle-promoting program, and that CTCF-depleted HSCs express higher levels of reactive
oxygen species (ROS). Importantly, in vivo treatment with an antioxidant partially rescued c-Kithi cell populations and their
quiescence. Altogether, our results suggest that CTCF is indispensable for maintaining adult HSC pools, likely by regulating
ROS-dependent HSC quiescence.
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INTRODUCTION
Hematopoiesis in the human body is primarily maintained by a
complex differentiation program initiated in hematopoietic
stem cells (HSCs).1 These cells undergo a tightly coordinated
regimen of self-renewal and differentiation that is ﬁnely
regulated by several molecular mechanisms, including (1) a
speciﬁc set of transcription factors, such as RUNX1,
GATA2, GFI1, and TAL1;1–3 (2) signaling pathways, such as
the Wnt/β-catenin and Notch pathways;4,5 and (3) bone
marrow (BM) niches.6 In addition, several reports emphasize
the critical roles of epigenetic and chromatin modiﬁcations in
maintaining HSC homeostasis.7–9 DNA methyltransferases
have been found to be important to HSC homeostasis and
differentiation by downregulating myeloid progenitor-related
factors, including GATA1, ID2 and CEBPα.10–12 The compo-
nents of polycomb-repressive complexes, including BMI-1,13
RAE2814 and RING1B,15 as well as the histone H2A deubiqui-
tinase MYSM1,16 have been shown to be critical in the
maintenance of HSC function. Another study has also
demonstrated that HSC function is controlled by the mediator
component MED12, which regulates H3K27Ac at enhancers of
key HSC genes.17 Further understanding how HSC homeostasis
and function are maintained by other epigenetic factors could
be important for developing new therapeutic strategies. Indeed,
epigenetic changes have been implicated in the pathogenesis of
myelodysplastic syndrome and acute myeloid leukemia.18
CCCTC-binding factor (CTCF) is a highly conserved
DNA-binding protein that contains an 11-zinc-ﬁnger domain.
CTCF shows a genome-wide distribution of DNA occupancy,
and 30–60% of its binding is cell type speciﬁc.19 Although
CTCF was ﬁrst described as a transcription factor,20 and
subsequently as a chromatin insulator,21 recent studies have
1Department of Environmental Medical Biology, Institute. of Tropical Medicine, Yonsei University College of Medicine, Seoul, Korea; 2BK21 PLUS Project for
Medical Science, Yonsei University College of Medicine, Seoul, Korea and 3Department of Dermatology, Cutaneous Biology Research Institute, Yonsei
University College of Medicine, Seoul, Korea
Correspondence: Dr H-P Kim, Department of Environmental Medical Biology, Institute of Tropical Medicine, Yonsei University College of Medicine, 50-1,
Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
E-mail: kimhp@yuhs.ac
4These authors contributed equally to this work.
Received 28 October 2016; revised 27 February 2017; accepted 20 March 2017
Experimental & Molecular Medicine (2017) 49, e371; doi:10.1038/emm.2017.124
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology
www.nature.com/emm
revealed that CTCF functions to mediate long-range DNA
interactions and to identify the borders of topologically
associated domains that contribute to three-dimensional
chromatin interactions.22–24 Topological remodeling of the
genome by CTCF can affect the expression of cell
differentiation-associated and function-associated genes.
Interestingly, CTCF has been shown to play multiple roles in
hematopoietic cell lineages, both in lymphoid and in myeloid
cells.25,26 Recently, we discovered that CTCF is required
for maintaining the systemic dendritic cell (DC) pools and
the self-renewal of epidermal Langerhans cells in a conditional
knockout (cKO) system.27 Nevertheless, the precise role of
CTCF in controlling HSC homeostasis remains unknown.
Here, we aimed to identify the homeostatic role of CTCF in
maintaining adult HSCs in mice. We generated inducible
CTCF-cKO mice and analyzed the HSC populations in
combination with the BM chimera approach. The CTCF-
dependent gene expression was assessed by microarray-based
transcriptome analysis.
MATERIALS AND METHODS
Mice
Mice carrying a conditional Ctcf allele (Ctcfﬂox) were described in our
previous study.27 The Ctcfﬂox mice were crossed with Rosa26-CreER
mice28 (CreER; kindly provided by Weonsang Simon Ro, Institute of
Gastroenterology, Yonsei University College of Medicine) to generate a
tamoxifen (TMX) -inducible systemic Ctcf-cKO strain (CTCF-cKO).
For Cre-mediated recombination, mice were intraperitoneally injected
with tamoxifen (Sigma-Aldrich; St Louis, MO, USA) dissolved in corn
oil (Sigma-Aldrich) for 4–5 consecutive days (2 mg day− 1). Wild-type
(WT) C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice were purchased
from The Jackson Laboratory (Bar Harbor, ME, USA). All animals
were bred in speciﬁc pathogen-free facilities at Yonsei University
College of Medicine. Age- and sex-matched CreER littermate mice
were used as WT controls throughout the study. All animal studies
were approved by the Department of Laboratory Animal Resources
Committee of the Yonsei University College of Medicine.
Blood cell count
Whole blood was collected from the superﬁcial facial vein of the
animals into EDTA-treated tubes at speciﬁed time points. The total
blood cell and differential counts were evaluated using a hematology
analyzer (HEMAVET 950FS, Drew Scientiﬁc).
Bone marrow transplantation
A total of 5 × 106 BM cells from CreER and CTCF-cKO mice
(CD45.2) were transplanted into lethally irradiated (9.5 Gy) B6.SJL
mice (CD45.1) or vice versa. To generate mixed BM chimeras,
2.5 × 106 BM cells from either CreER or CTCF-cKO mice (CD45.2)
were mixed with an equal number of BM cells from B6.SJL (CD45.1)
mice and transferred into the irradiated B6.SJL (CD45.1) mice. All
resulting chimeric mice were provided with water that contained
antibiotics (sulfamethoxazole/trimethoprim) for the ﬁrst two weeks.
Six to eight weeks after transplantation, Cre-mediated recombination
was induced with daily injections of tamoxifen. Thereafter, the BM
and spleen cells were harvested from the reconstituted mice and
analyzed.
Antibodies and ﬂow cytometry
Total BM cells were ﬂushed and harvested from both hind legs.
Single-cell suspensions from the spleen were obtained by enzymatic
digestion as previously described.27 Fluorochrome-conjugated
anti-mouse B220 (RA3-6B2), CD3 (145-2C11), CD4 (RM4-5), CD8
(53-6.7), CD11b (M1/70), CD11c (N418), CD19 (eBio1D3), CD16/32
(93), CD34 (RAM34), CD45.1 (A20), CD45.2 (104), CD48 (HM48-1),
CD117/c-Kit (2B8), CD135/Flt3 (A2F10), CD150 (TC15-12F12.2),
F4/80 (BM8), CD127/IL-7Rα (A7R34), Ki-67 (SolA15), Ly-6G
(RB6-8C5), Sca-1 (D7) and Siglec-H (eBio440C) antibodies were used
for surface immunophenotyping (eBioscience; San Diego, CA, USA).
Lineage-positive cells in the BM were excluded using the following
biotinylated antibodies, followed by treatment with APC-Cy7-
conjugated streptavidin: B220, CD3, CD4, CD8, CD11b, CD11c,
CD19, Gr-1, NK1.1 (PK136) and Ter119 (TER-119) (all from
eBioscience). Cell death and apoptosis were analyzed using an
Annexin V/propidium iodide (PI) staining kit (eBioscience). Stained
cells were acquired using a FACSVerse or LSRFortessa ﬂow cytometer
(BD Biosciences, San Jose, CA, USA). All ﬂow cytometry data were
analyzed with the FlowJo software (Treestar, Ashland, OR, USA).
Cell cycle assays
Complete RPMI medium (HyClone, Logan, UT, USA) that was
supplemented with 10% heat-inactivated fetal bovine serum
(HyClone), 50 μM of 2-mercaptoethanol, 2 mM of L-glutamine, 100
units per ml of penicillin, and 100 μg ml− 1 of streptomycin was used
for the cell culture. The cells were incubated in complete RPMI
containing 10 μg ml− 1 of Hoechst 33342 (Molecular Probes, Eugene,
OR, USA) for 45 min at 37 °C. After surface antigen staining, the
cells were ﬁxed and permeabilized, and subsequent nuclear staining
of Ki-67 was performed. The cell cycle was analyzed by ﬂow cytometer
after gating out doublet cells.
Measurement of reactive oxygen species
Total BM cells were incubated with 1 μM of 5-(and-6)-carboxy-2′,7′-
dichloroﬂuorescein diacetate (carboxy-DCFDA; Molecular Probes)
diluted in phosphate-buffered saline for 30 min at 37 °C in the dark.
After extensive washing with phosphate-buffered saline, the cells were
stained for lineage and HSC markers at 4 °C and assayed by ﬂow
cytometry.
Colony-forming unit assay
Colony-forming units were assessed using a Methocult assay (M03434,
Stem Cell Technologies; Vancouver, BC, Canada) according to the
manufacturer’s instructions. The number of rising colonies was
counted at speciﬁed time points. In brief, 2 × 104 total BM cells were
plated in methylcellulose medium containing recombinant mouse
stem cell factor (SCF), IL-3, IL-6 and erythropoietin and cultured at
37 °C in a 5% CO2 incubator for 10 to 14 days without changing the
medium.
In vivo N-acetyl-L-cysteine treatment
Daily, N-acetyl-L-cysteine (NAC; Sigma) was intraperitoneally injected
into WT and CTCF-cKO mice for 8 consecutive days at a dose
of 100 mg per kg of body weight during and after tamoxifen-induced
Ctcf genetic recombination.
Microarray
One day after the last tamoxifen treatment, BM single-cell suspensions
were prepared, and the LSKs were sorted using a FACSAria II cell
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sorter (BD Biosciences) at the Flow Cytometry Core Lab in the Avison
Biomedical Research Center (Yonsei University College of Medicine).
Sorted LSKs were immediately collected in TRIzol (Invitrogen,
Carlsbad, CA, USA), and the total RNA was extracted using the
isopropanol precipitation method. Sample preparation and microarray
data analyses were performed as described previously.27 The accession
number for the data reported in this paper is GEO: GSE88995.
Real-time quantitative polymerase chain reaction
Total RNA from puriﬁed cells was isolated using the Hybrid-R Total
RNA kit (GeneAll Biotechnology, Seoul, Korea) as described in our
previous study.27 cDNA was synthesized using PrimeScript RT Master
Mix (Takara Bio, Shiga, Japan). Quantitative real-time PCR was
performed using the ABI StepOnePlus Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) by monitoring the
synthesis of double-stranded DNA during various PCR cycles using
SYBR Green (Takara Bio). For each sample, duplicate test reactions
were analyzed for the expression of the gene of interest, and the results
were normalized using the level of Gapdh mRNA. Primer sequences
are listed in Supplementary Table 1.
Statistical analysis
The data were analyzed with unpaired Student’s two-tailed t-tests,
unless otherwise stated, using Prism software (GraphPad Software
Inc.; San Diego, CA, USA). Blood cell counts within the same mouse
before and after tamoxifen treatment were compared using paired
t-tests. All P-values o0.05 were considered statistically signiﬁcant.
Figure 1 Acute systemic CTCF ablation leads to hematopoietic failure. (a) The relative expression levels of Ctcf among various
stem/progenitor cells (data from ImmGen). (b) WT and CTCF-cKO mice were treated with TMX for 5 consecutive days, and genomic DNA
and total RNA from the BM were isolated at day 8. Efﬁcient Ctcf deletion by TMX treatment in CTCF-cKO mice at the DNA (left) and the
RNA (right) levels is shown. (c) Kaplan–Meier curves plotting the survival of WT and CTCF-cKO mice (n=10) are shown. (d) Peripheral
blood counts of control and CTCF-cKO mice at baseline and 10 days after the ﬁrst TMX injection (n=4−5). (e) Bone marrow counts
(femurs and tibiae) of WT and CTCF-cKO mice 8 days after TMX treatment (n=5). Data are from at least three independent experiments
with four or ﬁve mice per group. Error bars indicate the standard error of the mean (s.e.m.). **Po0.01; ***Po0.001; ns, not signiﬁcant.
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Figure 2 Acute systemic depletion of CTCF results in severe decreases in c-Kithi stem/progenitor cell numbers. (a, b) The surface levels of
c-Kit in lineage− cells (a) and the frequencies and absolute numbers of LSK (lineage−Sca-1+c-Kithi) and LK (lineage−Sca-1−c-Kithi) cells
(b) from WT and CTCF-cKO mice at 8 days after TMX injection. (c) The frequencies and absolute number of LT-HSCs (CD150+CD48−),
ST-HSCs (CD150−CD48−), MPP1 (CD150+CD48+) and MPP2 (CD150−CD48+) populations among LSKs are shown. (d) FACS analysis with
cell numbers of CMP (CD34+CD16/32−), GMP (CD34+CD16/32+) and MEP (CD34−CD16/32−) among the LK population are shown.
(e) FACS analysis and quantitation of CLP. Data are from at least three independent experiments with three or four mice per group. Error
bars indicate the s.e.m. *Po0.05; **Po0.01; ***Po0.001. FACS, ﬂuorescence-activated cell sorting; GMP, granulocyte-macrophage
progenitors; ST-HSC, short-term HSC.
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Figure 3 CTCF loss in the hematopoietic system leads to severe BM failure and consequent lethality. (a) The efﬁciency of chimerism was
analyzed in lineage-negative BM cells from CD45.1+ recipients transplanted with CD45.2+ donor BM. (b) Kaplan–Meier curves plotting the
survival of single chimeric mice (n=5–9). Statistical analyses were performed between (1) WT→CD45.1 and CTCF-cKO→CD45.1 and
(2) CD45.1→WT and CD45.1→CTCF-cKO. (c) Peripheral blood counts of control and CTCF-cKO→CD45.1 chimeric mice at 9 days after
the ﬁrst TMX injection (n=5). (d) Total BM cellularity for each chimera is shown. (e) Clinical pictures of WT and CTCF-cKO chimeras
showing anemic (upper and middle) and spontaneous hemorrhagic (lower) propensities. (f) The frequencies and absolute numbers of LSK
and LT-HSCs from WT and CTCF-cKO chimeras at 8 days after TMX injection. Data are from at least two independent experiments with
three or four mice per group. Error bars indicate the s.e.m. *Po0.05; **Po0.01; ***Po0.001; ns, not signiﬁcant.
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RESULTS
Loss of CTCF leads to rapid BM failure
To examine the relative expression levels of Ctcf mRNA in
primitive hematopoietic stem/progenitor cells, we analyzed the
Immunological Genome microarray database, which includes
data on a large number of immune cells and their progenitor
cell populations.29 Ctcf mRNA was expressed in all the subsets
of HSCs and progenitor cells examined (Figure 1a). To
determine whether CTCF is required for general hematopoiesis
in vivo, we used the Cre-loxP system to knockout the Ctcf gene
with injections of TMX in adult mice. In CTCF-cKO mice, Ctcf
ablation was achieved with intraperitoneal injections of TMX
after 5 consecutive days (Figure 1b). Within 10 to 14 days after
TMX treatment, all CTCF-cKO mice had died, while the
survival rate of the WT mice was not affected (Figure 1c). Next,
we analyzed the peripheral blood cell counts in these mice to
evaluate the effect of CTCF loss on overall hematopoiesis.
Although both mouse genotypes showed normal white blood
cell and platelet counts before CTCF deletion, TMX treatment
led to a signiﬁcant reduction in these hematological parameters
in CTCF-cKO mice (Figure 1d and Supplementary Figure 1).
Interestingly, red blood cell (RBC) counts decreased slightly in
both WT and CTCF-cKO groups upon treatment with TMX,
although the difference therein was not statistically signiﬁcant,
suggesting that TMX alone could have a possible adverse effect
on erythropoiesis. Importantly, CTCF-ablated mice exhibited
markedly lower total BM cellularity than the WT control mice
(Figure 1e). These data indicate that CTCF is critical to
hematopoiesis and that the acute loss of CTCF results in rapid
hematopoietic failure.
Acute depletion of CTCF results in the rapid shrinkage of
c-Kithi HSC and progenitor cell pools
As systemic depletion of CTCF led to rapid BM failure, we next
examined heterogeneous HSC populations by ﬂow cytometry.
CD117/c-Kit is a receptor for SCF that is highly expressed
on most primitive stem/progenitor cells in the BM.30,31
Surprisingly, within 8 days after CTCF ablation, we found a
marked reduction in Lineage− c-Kithi cells from the BM
(Figure 2a). Lineage− BM cells from CTCF-ablated mice also
exhibited lower expression of CD135/Flt3 and CD34
and increased expression of Sca-1 and CD16/32 compared
with cells from WT mice (Supplementary Figure 2).
Lineage− c-Kithi cell populations can be divided into
Lineage− Sca-1+c-Kithi (LSK) and Lineage− Sca-1−c-Kithi (LK)
subsets, which are HSC-enriched and early myeloid progenitor-
enriched compartments, respectively. In line with the observed
acute hematopoietic failure, we noted a marked decrease in
both the LSK and the LK populations after CTCF ablation
(Figure 2b). As HSCs reﬂect a hierarchy of stem cell
differentiation,1 we further assessed HSCs from the LSK
compartment using different surface markers (Supplementary
Figure 4 CTCF deﬁciency-mediated HSC depletion has both cell-non-autonomous and cell-autonomous effects. (a) The experimental
scheme of the generation and the use of mixed BM chimeras. (b) The frequencies of CD45.2+ BM-derived LT-HSCs from the TMX-treated
mixed chimeric mice. (c) Multiple early progenitor cells from the TMX-treated mixed chimeric mice at day 28 are shown. Data are from
two or three independent experiments with four or ﬁve mice per group. Error bars indicate the s.e.m. ***Po0.001.
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Figure 3). The most primitive, long-term reconstituting HSCs
(LT-HSCs), which are distinguishable from other LSK cells by
CD150+CD48− surface characteristics, were profoundly dimin-
ished in TMX-treated BM from CTCF-cKO mice (Figure 2c).
In addition, we also found fewer short-term HSCs and other
primitive multipotent progenitors upon CTCF deletion com-
pared with WT controls. In the myeloid progenitor compart-
ment, common-myeloid progenitors (CMPs), granulocyte-
macrophage progenitors and megakaryocyte-erythroid progeni-
tors (MEPs) were nearly absent from CTCF-cKO BM
(Figure 2d). However, the number of common lymphoid
progenitors (CLPs) was fairly preserved after CTCF depletion
compared with those of HSCs and myeloid progenitors
(Figure 2e). Accordingly, the population of splenic myeloid
cells, which are directly derived from BM myeloid progenitors,
was markedly reduced in CTCF-cKO mice; however, the
numbers of lymphoid T and B cells were not affected
(Supplementary Figure 4). These results suggest that CTCF is
required for the homeostatic maintenance of c-Kithi HSCs and
early progenitors in vivo.
Figure 5 The loss of CTCF results in the exhaustion of myeloid progenitors and their differentiation. (a and b) Gating strategies for
dendritic cells (a), red pulp macrophages, monocytes, and neutrophils (b) in the spleen at day 28 are shown. (c) The frequencies
of CD45.2+ BM-derived myeloid lineage cells from the spleen of TMX-injected mixed chimeric mice are shown. (d) The proportion of
CD45.2+ BM-derived LK cells is shown. (e) The number of total colonies from WT and CTCF-cKO mice cultured in methylcellulose
medium supplemented with myeloid-driving factors over 9 days. Data are from at least three independent experiments with four or ﬁve
mice per group. Error bars indicate the s.e.m. **Po0.01; ***Po0.001.
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Loss of CTCF in the hematopoietic compartment results in
the rapid exhaustion of HSCs
As TMX-inducible Cre recombinase is ubiquitously expressed
in the tissues of ROSA26-CreER mice, the observed hemato-
poietic failure and rapid lethality after inducing CTCF depletion
in the CTCF-cKO mice may have resulted from the dysfunction
of cells from the non-hematopoietic compartment. To
address this issue, we performed BM chimera experiments.
BM chimerism was consistently achieved at a rate of
~ 98% (Figure 3a). TMX treatment of both CTCF-cKO
BM-transplanted CD45.1 (CTCF-cKO→CD45.1) and CD45.1
BM-transplanted CTCF-cKO (CD45.1→CTCF-cKO) chimeras
showed similar decreases in survival compared with other
chimeras (WT→CD45.1 or CD45.1→WT), suggesting that
CTCF ablation in both radio-sensitive and radio-resistant
compartments led to rapid lethality (Figure 3b). Peripheral
blood and BM analysis revealed similar hematopoietic failure in
TMX-treated CTCF-cKO BM-transplanted CD45.1 chimeras,
as seen in the systemic CTCF-deﬁcient mice (Figures 3c and d).
Consistent with the decreased numbers of RBCs and platelets in
blood, CTCF-cKO BM chimeras exhibited severe anemic and
hemorrhagic clinical features (Figure 3e). Furthermore, TMX
treatment led to rapid losses of c-Kithi HSC/myeloid progenitor
cells in BM-speciﬁc CTCF-null chimeras (Figure 3f). These
results indicate that the ablation of CTCF in the hematopoietic
compartment is sufﬁcient to induce the rapid exhaustion of
HSCs, resulting in hematopoietic failure and mortality.
HSC homeostasis is ﬁnely regulated by heterogeneous cross-
talk between HSCs and the surrounding stromal components
within the BM niche.6 As CTCF ablation in CTCF-cKO mice
also occurred in BM stromal cells, CTCF deﬁciency-mediated
HSC exhaustion and the accompanied BM failure might have
resulted from HSC-extrinsic effects. To test this possibility, we
transplanted CD45.2+ WT or CD45.2+ CTCF-cKO BM cells
together with CD45.1+-supporting BM cells at a 1:1 ratio into
lethally irradiated CD45.1+ recipient mice. Six weeks after
reconstitution, the mixed BM chimeras were injected with
TMX to induce CTCF depletion, and the BM cells were
analyzed up to 4 weeks after treatment (Figure 4a). In contrast
to the systemic and BM-conﬁned CTCF-depleting experiments,
we found a moderate reduction in the number of LT-HSCs
derived from CTCF-null donors during the acute phase (day 8),
which eventually disappeared (day 28) (Figures 4b and c). These
results imply that the genetic loss of CTCF results in HSC
exhaustion in both cell-extrinsic and cell-intrinsic manners.
CTCF-deﬁcient HSCs show defective myeloid lineage
development
As CTCF depletion led to a marked reduction in the number of
c-Kithi stem/progenitor cells in BM, we next aimed to
Figure 6 CLP-derived lymphoid differentiation is less sensitive to CTCF depletion. (a and b) Gating strategies for T cells (a) and B cells
(b) in the spleen at day 28 are shown. (c) The frequencies of CD45.2+ BM-derived lymphoid lineage cells from the spleens of TMX-treated
mixed chimeric mice are shown. (d) The proportion of CD45.2+ BM-derived CLPs is shown. Data are from at least three independent
experiments with four or ﬁve mice per group. Error bars indicate the s.e.m. *Po0.05; **Po0.01; ***Po0.001.
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investigate the development of HSC-driven early myeloid
progenitors and the subsequent peripheral myeloid cells in
the mixed chimera system. In the spleen, all subsets of DCs
derived from CTCF-deﬁcient BM, including plasmacytoid
(Siglec-H+CD11c+), conventional CD8α+ (Siglec-H−CD11chi
CD8α+CD11b−) and CD11b+ (Siglec-H−CD11chiCD8α−
CD11b+) DCs, were markedly reduced compared with those
from WT BM (Figures 5a and c). Splenic monocytes
(CD11bhiF4/80−SSCloLy-6G−) and neutrophils (CD11bhiF4/80−
SSChiLy-6G+), which develop from the HSC-myeloid
Figure 7 CTCF deﬁciency leads to an augmented cell cycle progression in HSCs. (a) LSKs were sorted 24 h after the last TMX treatment.
Scatter plots show the raw expression levels (log2), and the number of genes that exhibited greater than two-fold increases in WT (lower)
and CTCF-cKO (upper) LSKs with a P-value of less than 0.05 is indicated. Outer green lines indicate the two-fold boundary. (b) Heat map
showing the genes that belong to the cell cycle biological process as revealed by the Gene Ontology analysis. (c) The expression levels of
the selected genes from (b) were conﬁrmed by real-time quantitative PCR. (d) Ki-67/Hoechst-based cell cycle analysis of LT-HSCs from WT
and CTCF-cKO mice at 8 days after TMX treatment. (e) Cell cycle assay of LT-HSCs from the mixed BM chimeric mice at days 0 and 8
after initiating TMX treatment. (f and g) Apoptosis proﬁles of multiple HSCs in non-chimeric (f) and mixed BM chimeric mice (g) 8 days
after TMX treatment. Data are from at least two or three independent experiments with four or ﬁve mice per group. Error bars indicate the
s.e.m. *Po0.05; **Po0.01.
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progenitor axis, also showed a marked reduction in the absence
of CTCF (Figures 5b and c). Meanwhile, however, F4/80+ red
pulp macrophages in the spleen (CD11bintF4/80+), which are
maintained by self-renewal without substantial monocyte
input, only partially declined after inducing CTCF depletion,
conﬁrming their distinct homeostasis in the steady-state
(Figures 5b and c).32,33 Consistent with the reductions in the
differentiated myeloid compartment after CTCF deletion,
myeloid progenitor LK cells in the BM from CTCF-deﬁcient
donors were scarce (Figure 5d). To delineate the role of CTCF
in the colony-forming capabilities of stem and myeloid
progenitor cells, we performed in vitro colony-forming
unit assays. Total untouched BM cells from either WT or
CTCF-cKO mice were plated in methylcellulose medium
supplemented with SCF, IL-3, IL-6, and erythropoietin,
followed by ex vivo TMX treatment. CTCF-cKO BM cells
Figure 8 CTCF maintains the c-Kithi HSC pool and quiescence in a ROS-dependent manner. (a and b) Intracellular ROS levels were
measured using CM-H2DCFDA from TMX-treated straight cKO mice (a) and chimeric mice (b) at 8 days after starting TMX treatment. The
MFI of the ROS levels was calculated. (c) The percentage of the c-Kit+ population in the Lin−Sca-1+CD150+CD48− cell population in the
indicated experimental group is shown. (d) The representative ﬂow cytometry plots of the lineage− population in WT and CTCF-cKO mice at
8 days after inducing CTCF depletion by TMX with or without NAC treatment. (e) Cell cycle analysis of LT-HSCs from WT and CTCF-cKO
mice treated with the same conditions as in d. Data are from two independent experiments with three to ﬁve mice per group. Error bars
indicate the s.e.m. *Po0.05; **Po0.01; ***Po0.001. MFI, mean ﬂuorescence intensity; ns, not signiﬁcant.
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treated with TMX showed marked decreases in colony-forming
units compared with WT BM cells (Figure 5e). These data
indicate that CTCF is critical in HSC-driven myeloid lineage
development both in vivo and ex vivo.
CLPs and lymphoid lineage cells are less sensitive to CTCF
ablation
We next examined the role of CTCF in lymphoid lineage
development. Similar to TMX-treated systemic CTCF-deﬁcient
mice, CTCF-ablated BM cells in the mixed chimeras gave rise
to signiﬁcant amounts of both CD4+ and CD8+ T cells in the
spleen, unlike those in the myeloid lineage experiments
(Figures 6a and c). B lymphocyte development was also
relatively preserved, as the frequency of B cells from the
CTCF-deﬁcient BM was only reduced to approximately half
that of the WT CD45.2+ BM-derived B cells (Figures 6b and c).
Furthermore, we observed a discrete population of
CTCF-deﬁcient CLPs from CTCF-ablated BM in the mixed
chimeras similar in number to T and B lymphocytes
(Figure 6d). Therefore, these results suggest that lymphoid
lineage development is only partially affected by CTCF deple-
tion in vivo.
CTCF deﬁciency results in defective HSC quiescence
To identify genes regulated by CTCF in hematopoietic
stem/progenitor cells, we performed microarray-based gene
expression analyses. LSK cells were sorted by ﬂow cytometry
after three treatments with TMX and subjected to microarray
experiments before the LSKs went missing (Supplementary
Figure 5a). Acute loss of CTCF led to rapid changes in the gene
expression proﬁles between WT and CTCF-deﬁcient LSKs
(Figure 7a). Subsequent systematic gene ontology analysis
revealed that CTCF-depleted LSKs express high levels of cell
cycle-promoting genes (Figure 7b), the results of which were
conﬁrmed by quantitative PCR (Figure 7c). In the steady state,
the maintenance of HSC quiescence is critical for regulating
stem cell pools. To determine whether HSC quiescence is
affected by CTCF deletion, we performed a Ki-67/Hoechst-
based cell cycle assay. Notably, CTCF-deﬁcient LSKs showed
signiﬁcant increases in the proportion of cells in the G1 and the
S-G2-M phases (Supplementary Figure 5b). Among LT-HSCs,
CTCF deﬁciency led to a marked reduction in the number
of cells in the G0 phase and increased the number of cells in
the G1 and the S-G2-M phases, reﬂecting a quiescence
defect (Figure 7d). Furthermore, cell cycle analyses performed
in the mixed chimera system revealed a rapid induction of
quiescence defects in LT-HSCs by CTCF ablation (Figure 7e).
However, CTCF-depleted HSCs, multiple progenitors and
differentiated lineage+ cells demonstrated similar levels of
cell death compared with that of WT cells, regardless of
supporting BM (Figures 7f and g and Supplementary
Figure 6). Collectively, these data demonstrate that CTCF is
critically involved in maintaining HSC quiescence in vivo.
CTCF maintains quiescence of HSCs by downregulating ROS
levels
Maintaining a low level of reactive oxygen species (ROS) is
essential to retaining HSC quiescence.34 HSCs maintain a low
intracellular level of ROS by adapting metabolic shift to
enhance glycolysis, which is associated with reduced mitochon-
drial oxidation and ROS generation.35–37 From our microarray
results, we noted that the levels of several ROS-regulating
genes, such as TNF, NCF1, AKT1 and SIRT5, were altered in
CTCF-depleted LSKs (Supplementary Table 2). In addition,
CTCF-deﬁcient LSKs had a higher level of the gene expression
of gluconeogenic enzyme fructose-1,6-bisphosphatase
1 (Fbp1), which may suppress glycolysis in HSCs (Supple-
mentary Figure 7).38 Thus, we examined intracellular
ROS production using the general oxidative stress indicator
CM-H2DCFDA. CTCF-depleted HSCs displayed marked
increases in ROS levels in both the acute systemic and the
BM-conﬁned CTCF ablation settings (Figures 8a and b). To
test whether increased ROS levels confer a severe loss of c-Kithi
stem/progenitor cells, we treated WT and CTCF-cKO mice
with the antioxidant NAC. Importantly, in vivo NAC treatment
signiﬁcantly recovered the depleted c-Kit+ cell populations
(Figure 8c) and the expression levels of c-Kit surface protein
(Supplementary Figure 8a) on the Sca-1+CD150+CD48− cells
from CTCF-cKO mice. In addition, treatment with NAC
partially restored the c-Kithi LSK population and its subset
divisions (Figure 8d and Supplementary Figure 8b). Further
cell cycle analysis revealed that NAC treatment caused a slight
increase in the number of cells in the quiescent G0 phase from
the CTCF-deﬁcient LT-HSC compartment, suggesting that the
increases in ROS were responsible for the defect in CTCF
ablation-mediated HSC quiescence (Figure 8e). Altogether,
these results indicate that CTCF maintains the c-Kithi HSC
pools and quiescence, partially in a ROS-dependent manner.
DISCUSSION
Hematopoietic differentiation is a multistep process that is
tightly controlled by complex molecular and cellular networks.
Although CTCF has been shown to regulate the cellular
development and differentiation of human erythroid cells,39
murine thymocytes,25 mature T cells,25,40 B cells41 and myeloid
lineage cells, including DCs,26,27,42 whether CTCF controls
the homeostasis of adult HSCs has been unknown. In the
present study, we generated a TMX-inducible CTCF-cKO
mouse system to conditionally ablate CTCF from the
adult hematopoietic system, as CTCF-null embryos experience
prenatal lethality.43
The combined genetic and BM transplantation approaches
used in our study demonstrated that acute systemic
and hematopoietic-speciﬁc ablation of CTCF leads to rapid
hematopoietic failure. Although peripheral blood analyses
showed a minor effect on RBC concentration, we noted severe
anemic clinical features in CTCF-cKO mice. As CTCF is
required for erythroid differentiation44 and for the chromatin
dynamics of globin genes,22 peripheral RBCs that are found in
CTCF-cKO mice may represent functionally immature
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erythroid cells. Therefore, deregulated RBC differentiation in
CTCF-cKO mice may cause lethality.
Notably, the ablation of CTCF in mice resulted in
severe decreases in the heterogeneous c-Kithi stem/progenitor
cell populations, including the most primitive LT-HSCs.
Subsequent co-transplantation with supporting BM was
able to delay the decreases in LT-HSCs, suggesting that the
exhaustion of HSCs by CTCF depletion has both cell-extrinsic
and cell-intrinsic effects. To the best of our knowledge, these
results are the ﬁrst to demonstrate the necessity of CTCF in the
maintenance of HSC pools in vivo. c-Kit is the surface receptor
of SCF, a cytokine that is essential for HSC self-renewal,
growth, and survival.45 Interestingly, a recent study reported
that MED12, a component of the Mediator complex, is
required for the transcriptional regulation of c-Kit in HSCs.17
As our CTCF-ablated mice showed reductions in c-Kithi HSCs,
assessing whether CTCF directly regulates c-Kit transcript
expression in our model in association with mediator and/or
chromatin modiﬁers could prove to be of value.
The delayed disappearance of CTCF-deﬁcient HSCs in the
mixed chimeras implicated a possible role for CTCF in BM
niche-supporting cells for maintaining HSC homeostasis. HSC
niches are comprised of heterogeneous cell populations,
such as osteoblasts, CXCL12-abundant reticular cells, lepr+
perivascular cells, endothelial cells, and macrophages.6
However, how CTCF regulates the HSC niche has not yet
been understood. Recently, a population of DARC+ macro-
phages has been shown to be crucial for maintaining LT-HSC
quiescence.46 As multiple populations of tissue macrophages
were moderately decreased by conditional CTCF deletion
using the LysM-Cre system,47 it remains to be examined
whether the pool and function of DARC+ macrophages in
the BM are also regulated by CTCF, which may ultimately lead
to non-autonomous HSC exhaustion.
Through intermediate multipotent progenitor cells, HSCs
continuously give rise to both myeloid and lymphoid progeni-
tor cells.1,2 Interestingly, our mixed chimera experiments
demonstrated that CTCF-deﬁcient HSCs fail to give rise to
myeloid lineage cells, while lymphoid lineage development was
relatively preserved. A previous study using CTCF-silenced
common-myeloid progenitors (CMPs) showed that CTCF
knockdown increases the rate of CMP differentiation
in vitro.26 As CMPs arise directly from HSCs and there is a
lack of further CMP input from HSCs in the in vitro system,
our data suggest that CTCF is required in order to sustain
myeloid lineage development in vivo. For defective myeloid
differentiation, we assume that the CTCF-mediated chromatin
dynamics of certain loci, such as Irf8 and Sfpi1, may be pivotal
for ensuring HSCs differentiate into early myeloid lineage
cells.48 In lymphoid lineage development, CTCF has been
shown to mediate the silencing of the B cell lymphoma
oncogene BCL6, and CTCF haploinsufﬁciency leads to multiple
lymphomas in vivo, which may be associated with the longer
survival and maintenance of CTCF-deﬁcient lymphoid lineage
cells in our study.49,50 Future work will be needed to clarify the
possible role of CTCF in lineage commitment.
In the absence of speciﬁc mitogenic stimuli, HSCs remain in
a quiescent or a dormant state.51 The microarray analyses
conducted in the current study revealed that CTCF-deﬁcient
hematopoietic stem/progenitor cells show defective quiescence
and striking elevations in cell cycle-promoting gene expression.
However, CTCF has been shown to be associated with cell cycle
progression and cell cycle arrest in a cell type-dependent
manner. CTCF promotes cell cycle progression and the
proliferation of αβ T cells in the thymus,25 epidermal Langer-
hans cells,27 and human embryonic stem cells,52 while it
negatively regulates the cell cycle in several types of tumor
cells.53–55 As our transcriptome analysis was conducted using
LSK cells before a loss of surface c-Kit expression, any increase
in the cell cycle program would have been, in part, directly
regulated by CTCF deﬁciency at the transcription level.
Under the hypoxic conditions of the BM, low levels
of intracellular ROS are critical to maintaining HSC
quiescence.34,56 According to the intracellular ROS level, HSCs
can be divided into ROShigh and ROSlow fractions, and ROShigh
HSCs have a higher myeloid differentiation capacity, indicating
a positive correlation between ROS level and myeloid
differentiation status.57–61 In the present study, CTCF-ablated
HSCs showed marked elevations in their ROS levels that
coincided with considerable decreases in the number of cells
in the quiescence phase. The in vivo administration of the
antioxidant NAC recovered the c-Kit+ population and defective
quiescence in HSCs, implying that CTCF-mediated ROS
regulation is crucial to HSC maintenance. Our microarray
data supported the idea that CTCF transcriptionally regulates
several ROS-associated genes in HSCs. An increase in the level
of inﬂammatory products, including TNF and IFN-γ, has been
implicated in inducing HSC proliferation and exhaustion.62,63
Interestingly, we found that Fbp1 was highly elevated in CTCF-
depleted LSKs. A previous study showed that cancer stem cells
exhibited epigenetically silenced Fbp1 expression to maintain
their active glycolysis and lower ROS generation status, which
are metabolically stem cell-favorable environments.38,64 Thus,
we speculate that CTCF is somehow involved in the regulatory
process of oxidative stress in HSCs by promoting glycolysis
through silencing Fbp1 expression. Consistent with our
ﬁndings, a recent study found that, in collaboration with
Cockayne syndrome group B protein, CTCF protects cells
from oxidative stress.65 Accordingly, we suggest that CTCF
may have beneﬁcial antioxidative activity in certain type of
cells, including HSCs, by supporting metabolic glycolysis.
Further studies will be needed to identify the CTCF-mediated
metabolic characteristics of HSCs.
In summary, we have elucidated a role for CTCF in HSC
homeostasis using genetic approaches. CTCF supports the
homeostatic maintenance of HSC pools by sustaining HSC
quiescence in a ROS-dependent manner. Further study is
required to translate our ﬁndings into clinical applications to
improve the outcomes of HSC transplantation or anti-leukemic
therapies through modulating CTCF levels by RNA interfer-
ence or genome editing of speciﬁc CTCF-binding sites
in vivo.66,67
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